aTyr Pharma Inc 主要终点设定为第48周FVC变化;关键次要终点为KSQ-Lung评分较基线的变化

美股速递
May 12

aTyr Pharma Inc宣布,其临床试验的主要疗效终点将设定为第48周时用力肺活量(FVC)的变化情况。与此同时,研究的关键次要终点则确定为KSQ-Lung评分相对于基线的改变。这一设定明确了该生物制药公司后续临床数据评估的核心方向。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10